Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies
10 Luglio 2024 - 2:00PM
Business Wire
- Express Genes enable faster turnaround
times
- Twist Express Antibodies, CHO starting at 13
business days
- Twist Express Antibodies, HEK293 starting at
10 business days
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the expansion of
its high-throughput antibody portfolio with the launch of a CHO
cell line for Twist Express Antibodies. Twist also offers HEK293
expression Twist Express Antibodies.
“With the majority of biotherapeutic drugs manufactured in CHO
cell lines, expressing small-scale therapeutic antibody candidates
in CHO for screening has become a vital first step to ensure
successful downstream scale-up. We now provide a comprehensive
portfolio of antibody production to further serve the biopharma
market by offering both HEK293 with reduced turnaround times
enabled by our Express Genes as well as the newly launched CHO cell
line for Twist Express Antibodies,” said Emily M. Leproust, Ph.D.,
CEO and co-founder of Twist Bioscience. “By taking on the process
of antibody development from sequence to protein, we meet the needs
of therapeutic developers who currently make their own antibodies,
a costly bottleneck in the discovery pipeline, providing them with
a cost-effective, customizable, and scalable offering to support
their research.”
Using its high-throughput antibody production workflow, Twist
can generate large quantities of small-scale distinct antibodies
for candidate and drug discovery screening. Antibodies are created
from user-defined sequences using the customer’s expression system
of choice, either CHO or HEK293. Twist Express Antibodies are
sequence-perfect and high quality, delivered in as few as 10
business days.
Twist Express Antibodies, CHO
Twist Express Antibodies, CHO, are developed using a
high-throughput antibody production workflow that yields IgG
antibodies in quantities ranging from 15 μg up to 3,000 μg. The
antibodies are made using sequence-verified perfect clonal genes
for high quality. Twist also provides yield data on each antibody
sequence to be used as a screening tool for candidate selection as
well as control yield data to provide peace of mind and confidence
of successful transfection and protein production. Turnaround time
for Twist Express Antibodies, CHO, starts at 13 business days.
Twist Express Antibodies
Twist Express Antibodies provide a comprehensive and efficient
solution to antibody production and purification. The process
begins with a customer entering antibody sequences into Twist’s
eCommerce ordering platform, where bioinformatic screening and gene
scoring is used to filter out potentially non-viable sequences.
From there, synthetic DNA is generated, which is either cloned into
one of Twist’s IgG scaffold vectors, or a vector of the customer’s
choice. Twist’s silicon-based DNA synthesis platform enables the
simultaneous production of up to thousands of antibody genes, which
enables flexible production of tens to thousands of distinct
antibodies. Twist sequences the antibody genes to ensure that the
precise order has been cloned correctly, every time. These
antibodies are then produced in CHO or HEK293 cells, resin
purified, and have a turnaround time starting at 10 business days
for HEK293 and 13 business days for CHO.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995 including, but not limited to, statements regarding the
ability of Twist Express Antibodies to provide a comprehensive and
efficient solution to antibody production and purification, as well
as our ability to meet the needs of therapeutic developers who
currently make their own antibodies by providing them with a
cost-effective, customizable, and scalable offering to support
their research. Forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may
cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the ability to achieve the expected benefits of Twist
Bioscience’s restructuring activities and reduced investments in
DNA data storage; the ability to attract new customers and retain
and grow sales from existing customers; the ability of Twist
Bioscience to achieve sufficient revenue to achieve or maintain
positive cash flow from operations or profitability in any given
period will depend heavily on the success of our existing products
and the development and commercialization of additional products in
the synthetic biology, biologic drug and data storage industries;
risks and uncertainties of rapidly changing technologies and
extensive competition in synthetic biology that could make the
products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies and to achieve expected benefits from
acquisitions; supply chain and other disruptions; risks of third
party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the SEC on November 21, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240710374255/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Gen 2024 a Gen 2025
